BeStock  
Stocks › DNLI

Denali Therapeutics DNLI

US equityMarket cap rank #2435Biotechnology
$19.91 −$0.09 (-0.45%)
Pre-market · Oct 6, 8:20 am ET · After hours $19.91 0.00%
Open$20.09
Prev close$20.00
Day range$19.54 – $20.09
Volume1.72M
Market cap$3.18B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-7.0x
CheapRich

Above its usual level · 68th percentile, 5-year average -4.2x

Price / book3.8x
CheapRich

Above its usual level · 66th percentile, 5-year average 3.3x

#3960 of 5315 stocks by PB (1 = cheapest)

Price / sales883.1x
CheapRich

Around its usual level · 57th percentile, 5-year average 972.2x

#5068 of 5147 stocks by PS (1 = cheapest)

P/E over five years

-40x11x63x115xOct '21Apr '24Oct '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$20.26
Price vs. fair value-1.7%Close to the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 3.81 – 3.27 66% (pricier than usual) #3960 of 5315 (1 = cheapest)
PE -7.01 -7.25 -4.15 68% (pricier than usual) –
PS 883.06 33.48 972.21 57% (pricier than usual) #5068 of 5147 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Morningstar view

Star rating★★★
Fair value estimate$20.26
Economic moatNone
UncertaintyVery High

Discussion

No comments yet — be the first to weigh in on DNLI.

Leave a comment

Scroll to Top